Fusing cardiac stem cells with platelet nanovesicles can increase the stem cells’ ability to find and remain at the site of heart attack injury and enhance their effectiveness in treatment, according to a new pilot study using an animal model. Cardiac stem cell therapy is a promising treatment for heart attack patients, but directing the cells to the site of an injury – and getting them to stay there – has remained challenging.
North Carolina State University researcher Ke Cheng and his team wondered if it would be possible to co-opt a platelet’s ability to locate and stick to an injury site without inducing clotting.
“Platelets can home in on an injury site and stay there, and even in some cases recruit a body’s own naturally occurring stem cells to the site, but they are a double-edged sword. That’s because once the platelets arrive at the site of injury, they trigger the coagulation processes that cause clotting. In a heart-attack injury, blood clots are the last thing that you want,”
said Cheng, associate professor of veterinary medicine and associate professor in the NC State/UNC Joint Department of Biomedical Engineering.
Platelet Nanovesicles Decor
The researchers found that adhesion molecules (a group of glycoproteins) located on the platelet’s surface were responsible for its ability to find and bind to an injury. So the team created platelet nanovesicles from these molecules, and then decorated the surface of cardiac stem cells with the nanovesicles,
“The nanovesicle is like the platelet’s coat,” Cheng says. “There isn’t any internal cellular machinery that could activate clotting. When you place the nanovesicle on the stem cell, it’s like giving the stem cell a tiny GPS that helps it locate the injury so it can do its repair work without any of the side effects associated with live platelets.”
In a proof-of-concept study involving a rat model of myocardial infarction, twice as many platelet nanovesicle decorated cardiac stem cells, or PNV-CSCs, were retained in the heart than non-decorated cardiac stem cells. The rodents were monitored for four weeks.
Overall, the rats in the PNV-CSC group showed nearly 20 percent or higher cardiac function than the control CSC group.
No Negative Side Effects
A small pilot study in a pig model also demonstrated higher rates of stem cell retention with PNV-CSCs, though the team did not perform functional studies. A future follow-up study is planned.
“Platelet nanovesicles do not affect the performance of the cardiac stem cells, and are free from any negative side effects,” Cheng says. “Hopefully we will be able to use this approach to improve cardiac stem cell therapy in clinical trials in the future.”
The work research supported by US National Institute of Health, NC State University Chancellor’s Faculty Excellence Program, NC State Chancellor’s Innovation Fund, University of North Carolina General Assembly Research Opportunities Initiative, and the National Natural Science Foundation of China.
Junnan Tang, Teng Su, Ke Huang, Phuong-Uyen Dinh, Zegen Wang, Adam Vandergriff, Michael T. Hensley, Jhon Cores, Tyler Allen, Taosheng Li, Erin Sproul, Emily Mihalko, Leonard J. Lobo, Laura Ruterbories, Alex Lynch, Ashley Brown, Thomas G. Caranasos, Deliang Shen, George A. Stouffer, Zhen Gu, Jinying Zhang & Ke Cheng Targeted repair of heart injury by stem cells fused with platelet nanovesicles Nature Biomedical Engineering 2, 17–26 (2018) doi:10.1038/s41551-017-0182-x